+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The inhibition of the high sensitive peripheral nerve soluble esterases by mipafox. A new mathematical processing for the kinetics of inhibition of esterases by organophosphorus compounds

The inhibition of the high sensitive peripheral nerve soluble esterases by mipafox. A new mathematical processing for the kinetics of inhibition of esterases by organophosphorus compounds

Toxicology Letters 151(1): 171-181

In the study of organophosphorus (OP) sensitive enzymes, careful discrimination of specific components within a complex multienzymatic mixture is needed. However, standard kinetic analysis gives inconsistent results (i.e., apparently different kinetic constants at different inhibitor concentration) with complex multienzymatic mixtures. A strategy is now presented to obtain consistent kinetic parameters. In the peripheral nerve, soluble carboxylesterases measured with the substrate phenylvalerate (PV) are found with extremely high sensitivity to some inhibitors. Tissue preparations were preincubated with mipafox at nanomolar concentrations (up to 100 nM) for different inhibition times (up to 180 min). Inhibition data were analyzed with model equations of one or two sensitive (exponential) components, with or without resistant components. The most complex model was %act=A1e-k1It+A2e-k2It+AR (step 1). From the curve with the highest mipafox concentration (100 nM), the amplitude for the resistant component was determined as AR=15.1% (step 2). The model equation with a fixed AR value was again applied (step 3) to deduce the second-order inhibition rate constants (k1=2.6 x 10(6) M-1 min-1 and k2=0.28 x 10(6) M-1 min-1), being conserved consistently throughout all mipafox concentrations. Finally, using fixed values of AR, k1, and k2, the amplitudes for the two exponential (sensitive) components (A1 and A2) were re-estimated (A1=50.2% and A2=34.2%). The operational process was internally validated by the close similarity with values obtained by directly fitting with a three-dimensional model equation (activity versus time and inhibitor concentration) to the same inhibition data. Carboxylesterase fractions separated by preparative chromatography showed kinetic properties consistent with the kinetically discriminated components. As practical conclusion, for routine analysis of esterases in toxicological studies, a simplified procedure using the inhibition with mipafox at 30 nM, 1 microM, and 1 mM for 30 min is suggested to discriminate the main esterase components in soluble fraction preparations.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 012662409

Download citation: RISBibTeXText

PMID: 15177652

DOI: 10.1016/j.toxlet.2004.04.006

Related references

A new mathematical processing for the kinetics of inhibition of esterases by organophosphorus compounds The inhibition of peripheral nerve soluble esterases by mipafox as a model. Toxicology Letters (Shannon) 116(Suppl 1): 73, September 1st, 2000

High and permanent inhibition of peripheral nerve soluble esterases by mipafox and S9B, a selective NTE inhibitor, suggest their potential role as neuropathy targets. Neurotoxicology (Little Rock) 21(4): 635, 2000

Kinetics of inhibition of soluble peripheral nerve esterases by PMSF: a non-stable compound that potentiates the organophosphorus-induced delayed neurotoxicity. Archives of Toxicology 86(5): 767-777, 2012

Properties of phenyl valerate esterase activities from chicken serum are comparable with soluble esterases of peripheral nerves in relation with organophosphorus compounds inhibition. Toxicology Letters 142(1/2): 1-10, 2003

Model equations for the kinetics of covalent irreversible enzyme inhibition and spontaneous reactivation: esterases and organophosphorus compounds. Critical Reviews in Toxicology 39(5): 427-448, 2009

In vivo protection from DFP inhibition of peripheral nerve soluble esterases by paraoxon. Toxicology Letters (Shannon) 135(Suppl 1): S157, September 15th, 2002

Inhibition with spontaneous reactivation and the "ongoing inhibition" effect of esterases by biotinylated organophosphorus compounds: S9B as a model. Chemico-Biological Interactions 187(1-3): 397-402, 2010

Inhibition of rat liver esterases by organophosphorus compounds. Nature London 213: 202-203, 1967

Peripheral nerve soluble esterases are spontaneously reactivated after inhibition by paraoxon: implications for a new definition of neuropathy target esterase. Chemico-Biological Interactions 119-120: 541-550, 1999

In vivo inhibition by mipafox of soluble and particulate forms of organophosphorus neuropathy target esterase (NTE) in hen sciatic nerve. Toxicology Letters 71(1): 47-51, 1994

Inhibition with spontaneous reactivation of carboxyl esterases by organophosphorus compounds: paraoxon as a model. Chemical Research in Toxicology 24(1): 135-143, 2011

Comparative sensitivities of avian neural esterases to in vitro inhibition by organophosphorus compounds. Toxicology Letters 36(2): 197-204, 1987

Biosensor analysis of blood esterases for organophosphorus compounds exposure assessment: approaches to simultaneous determination of several esterases. Chemico-Biological Interactions 187(1-3): 312-317, 2010

Organophosphorus inhibition and heat inactivation kinetics of particulate and soluble forms of peripheral nerve neuropathy target esterase. Journal of Biochemical Toxicology 10(4): 211-218, 1995

Studies on ali-esterases and other lipid-hydrolysing enzymes. 3. Inhibition of the esterases of pancreas. Biochemical Journal 61(3): 521-528, 1955